Datametrex AI (TSXV: DM) announced this morning that it has obtained non-exclusive rights to a COVID-19 test kit that currently has approval in a number of jurisdictions for use, including Canada. The test kit is the fourth COVID-19 test kit that Datametrex has secured the rights to, and is known as 1copy™ COVID-19 qPCR Multi Kit.
The 1copy test kit is a nucleic test kit that currently has Health Canada approval for use as a COVID-19 test kit, along with approvals for use in Saudi Arabia and the European Economic Area. The kit, which consists of a swab and can return results in as little as two hours, consists of a nasopharyngeal swab and oropharyngeal swab. The test kit is developed and manufacturing by 1drop Inc in South Korea, a spin-off from Samsung Electronics C-Lab program.
The test kits are immediately available for sales orders in Canada, however the ability of Datametrex to fulfill any order for product is dependent upon the availability of test kits from the manufacturer at time of order. If ordered by the Canadian government, the products will be shipped directly to the government or hospitals, without Datametrex being involved in the shipping, warehousing or distribution process.
Datametrex AI last traded at $0.18 on the TSX Venture.
Information for this briefing was found via Sedar and Datametrex AI. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
